Home / Archive by category "News"


NEWS: Berlin Cures Announces Formation of Scientific Advisory Board

Berlin Cures Announces Formation of Scientific Advisory Board Inaugural Members Include Leading Experts in Cardiology and Autoimmunity ZUG, Switzerland, May 23, 2018 /PRNewswire/ -- Drug developer Berlin Cures today announced the formation of a Scientific Advisory Board (SAB) and the appointment of its first two members, Prof. Beda M. Stadler and Prof. Wilhelm Vetter, to help advance the cli...
Read More

NEWS: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study

BC007 Eliminates Autoantibodies Linked to Disease in 80% of Patients First Drug to Attack the Cause of Dilated Cardiomyopathy ZUG, Switzerland, and BERLIN, Feb. 26, 2018 – The first drug designed to eliminate autoantibodies that are a major cause of heart failure and to treat heart failure symptoms was effective and well-tolerated in a Phase 1 clinical study, according to an oral presentatio...
Read More

NEWS: Phase-1 clinical study 

Berlin Cures Holding AG announces start of phase-1 study of BC007 ZURICH (Switzerland), November 14, 2016 --  Berlin Cures Holding AG announces the start of the clinical Phase-1-first-in-human-study of its drug candidate BC007. The study is a 2-part design with part 1 being a randomized, double-blinded, ascending single-dose study in healthy subjects, followed by part 2, which is an open, ascen...
Read More